Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]

International Agency for Research on Cancer Joerger, 2013, Treatment of breast cancer in the elderly: a prospective, population-based Swiss study, J Geriatr Oncol, 4, 39, 10.1016/j.jgo.2012.08.002 Howie, 2019, Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis, J Clin Oncol, 37, 3475, 10.1200/JCO.18.02217 Cardoso, 2020, 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), Ann Oncol, 31, 1623, 10.1016/j.annonc.2020.09.010 Biganzoli, 2012, Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA), Lancet Oncol, 13, e148, 10.1016/S1470-2045(11)70383-7 Cortes, 2011, Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet., 377, 914, 10.1016/S0140-6736(11)60070-6 Muss, 2014, Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer, Oncologist., 19, 318, 10.1634/theoncologist.2013-0282 Swami, 2012, Eribulin -- a review of preclinical and clinical studies, Crit Rev Oncol Hematol, 81, 163, 10.1016/j.critrevonc.2011.03.002 McIntyre, 2014, Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer, Breast Cancer Res Treat, 146, 321, 10.1007/s10549-014-2923-9 Wilks, 2014, Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer, Clin Breast Cancer, 14, 405, 10.1016/j.clbc.2014.04.004 Calhoun, 2003, Psychometric evaluation of the functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy, Int J Gynecol Cancer, 13, 741 Kaufman, 2015, Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, 33, 594, 10.1200/JCO.2013.52.4892 Yuan, 2019, Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial, Eur J Cancer, 112, 57, 10.1016/j.ejca.2019.02.002 Smith, 2020, Phase II study of eribulin mesylate administered biweekly in patients with human epidermal growth factor receptor-2-negative metastatic breast cancer, Clin Breast Cancer, 20, 160, 10.1016/j.clbc.2019.09.007 Takashima, 2016, A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer, Springerplus., 5, 164, 10.1186/s40064-016-1833-1 Rau, 2018, Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan, Breast Cancer Res Treat, 170, 583, 10.1007/s10549-018-4778-y Maeda, 2017, Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes, Breast., 32, 66, 10.1016/j.breast.2016.12.017 Ortega, 2019, Phase II, multicenter, single-arm trial of Eribulin as first-line therapy for patients with aggressive taxane-pretreated HER2-negative metastatic breast cancer: the MERIBEL study, Clin Breast Cancer, 19, 105, 10.1016/j.clbc.2018.12.012